BioVie reports 82% responder rate in Phase 2 Alzheimer's study; Phase 3 on track for mid-2023 readout

BIOVIE INC.

82% of MCI/mild AD patients improved cognition (modified ADAS-Cog12) after 3 months; mean improvement -2.6 points (p=0.0046).
Phase 3 NE3107 Alzheimer's trial has enrolled >50% of 316 patients; topline data expected mid-2023.
Phase 2 Parkinson's NE3107 trial expected to read out by end of 2022; early blinded data consistent with animal studies.
Phase 2b BIV201 ascites trial enrollment slowed by COVID; topline data now expected mid-2023.
Full data from exploratory Alzheimer's study to be presented at CTAD conference Nov 29–Dec 2, 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.